Clinical Trial Update: Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase I/IIa study of BR790 in combination with tislelizumab in adults with advanced solid tumors is in early stages with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• BR790
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Gopherwood Biotech Co., Ltd. | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: UNKNOWN